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1. INTRODUCTION {#dom12817-sec-0001}
===============

Dipeptidyl peptidase‐4 (DPP‐4) inhibitors are widely used in treatment of type 2 diabetes (T2D).[1](#dom12817-bib-0001){ref-type="ref"}, [2](#dom12817-bib-0002){ref-type="ref"} DPP‐4 inhibitors increase biologically intact forms of glucose‐dependent insulinotropic polypeptide (GIP) and glucagon‐like peptide‐1 (GLP‐1), both of which enhance glucose‐induced insulin secretion from pancreatic β‐cells.[3](#dom12817-bib-0003){ref-type="ref"}, [4](#dom12817-bib-0004){ref-type="ref"} GLP‐1 suppresses glucagon secretion from pancreatic α‐cells when glucose levels are high,[^5^](#dom12817-bib-0005){ref-type="ref"}, [^6^](#dom12817-bib-0006){ref-type="ref"} whereas GIP augments glucagon secretion in response to hypoglycaemia.[7](#dom12817-bib-0007){ref-type="ref"}, [8](#dom12817-bib-0008){ref-type="ref"}, [9](#dom12817-bib-0009){ref-type="ref"}, [10](#dom12817-bib-0010){ref-type="ref"} Thus, enhancement of GIP and GLP‐1 actions by DPP‐4 inhibitors should contribute, not only to amelioration of hyperglycaemia, but also to mitigation of severe hypoglycaemia. It was reported that the DPP‐4 inhibitor vildagliptin enhances the glucagon response to hypoglycaemia in drug‐naïve individuals with T2D,[11](#dom12817-bib-0011){ref-type="ref"} whereas the glucagon response to hypoglycaemia was not affected by GLP‐1 receptor (GLP‐1R) agonists.[12](#dom12817-bib-0012){ref-type="ref"}, [13](#dom12817-bib-0013){ref-type="ref"} This might suggest differing effects of DPP‐4 inhibitors and GLP‐1R agonists on the glucagon response to hypoglycaemia, which needs to be examined in head‐to‐head studies. In this study, we compared effects of the DPP‐4 inhibitor linagliptin with those of the GLP‐1R agonist liraglutide on the responses to hypoglycaemia of glucagon and other counter‐regulatory hormones in Japanese individuals with T2D.

2. METHODS {#dom12817-sec-0002}
==========

2.1. Study protocol {#dom12817-sec-0003}
-------------------

This was a multi‐centre, randomized, prospective, open‐label, 2‐arm parallel comparative, exploratory study in Japanese individuals with T2D (UMIN‐CTR clinical trial registration number: UMIN000014417). Those eligible were randomized in a 1‐to‐1 ratio to a linagliptin or liraglutide treatment group by computer‐based dynamic allocation, taking gender, age and BMI into consideration for stratified randomization based on screening results at visit 1 (V1, week −4). A meal tolerance test (MTT) and stepped hyperinsulinaemic glucose clamp test (SHGCT) were performed at visit 2 (V2, day 0) and visit 3 (V3, day 14); blood samples were obtained and analysed as described in File S1. Subjects received study medication for 14 days (days 1‐14), linagliptin 5 mg once daily or liraglutide 0.3 mg via subcutaneous injection once daily from day 1 to day 6 and 0.6 mg from day 7 to day 14. Liraglutide up to only 0.9 mg once daily is the dosage approved in Japan. Subjects were recruited and screened in 2 medical institutions in Osaka and Fukuoka, Japan after obtaining approval of the respective ethics committees. Randomization was performed at A2 Healthcare Corp in Tokyo, Japan. Data were collected in an inpatient ward of the medical institution in Fukuoka, Japan. Recruitment of subjects began July 5, 2014 and the last follow‐up date was April 20, 2015. Written informed consent was obtained from all subjects.

2.2. Study population {#dom12817-sec-0004}
---------------------

Eligible Japanese individuals with T2D were age 40‐70 years with a body mass index (BMI) \< 30 kg/m^2^, and a treatment history of a single oral hypoglycaemic agent with HbA1c 6.0% to 8.0% (42‐64 mmol/mol) or no drug treatment with HbA1c 6.0% to 8.5% (42‐69 mmol/mol). Individuals requiring insulin therapy, or those treated with insulin, DPP‐4 inhibitors or GLP‐1 receptor agonists during the 4 weeks before informed consent, or those treated with pioglitazone during the 12 weeks before informed consent were excluded, as were those with cardiac failure or history of cerebro‐cardiovascular disease or pancreatitis. The sample size was not based on a power calculation as this was an exploratory pilot study; however, the sample size would seem to be appropriate in the context of previous, related studies.[9](#dom12817-bib-0009){ref-type="ref"}, [11](#dom12817-bib-0011){ref-type="ref"}

2.3. Study assessments {#dom12817-sec-0005}
----------------------

Major outcomes were changes in glucagon and other counter‐regulatory hormones (ie, epinephrine, norepinephrine, cortisol and growth hormone \[GH\]) during SHGCT following 2‐week treatment with linagliptin or liraglutide in the per protocol set (PPS) population (ie, subjects who received 14‐day administration of study medication with successful completion of SHGCT on both V2 and V3). All adverse events (AE) were collected and AE by system organ class/preferred terms, serious adverse events (SAE) and discontinuation from AE were summarized for the full analysis set (FAS) population (ie, subjects who received at least 1 dose of study medication, with data from at least 1 point of safety available after drug administration, regardless of successful completion of SHGCT on either V2 or V3).

2.4. Statistical analysis {#dom12817-sec-0006}
-------------------------

All analyses were performed using SAS version 9.4 (SAS Institute, Inc., Cary, North Carolina). Results are reported as mean ± SE unless otherwise stated. Area‐under‐the curve (AUC) of each measurement was calculated according to the trapezoidal rule. Repeated measures were analysed with mixed‐design analysis of covariance (ANCOVA). The changes of each measurement from 225 to 255 minutes were tested using two sample *t* test. A 2‐sided *P* value \< .05 was taken to indicate significant difference.

3. RESULTS {#dom12817-sec-0007}
==========

Thirty‐five screened subjects were randomized to the linagliptin treatment group or the liraglutide treatment group; they received study assessments at V2 and V3 and were analysed as the FAS population (Table [1](#dom12817-tbl-0001){ref-type="table-wrap"} and Figure S1). Six of them did not reach the target blood glucose level in the hypoglycaemic phase at V2 and/or V3 and were excluded from the PPS population.

###### 

Demographic and baseline characteristics of full analysis set and per protocol set populations

                                 Full analysis set   Per protocol set                                            
  ------------------------------ ------------------- ------------------ ------ ---------------- ---------------- ------
  n (male/female)                18 (13/5)           17 (12/5)                 15 (11/4)        14 (10/4)        
  Age (years)                    58.56 ± 7.81        57.76 ± 7.63       .764   59.53 ± 7.12     56.79 ± 7.66     .326
  BMI (kg / m^2^)                23.82 ± 2.29        23.98 ± 3.15       .871   23.47 ± 1.93     23.88 ± 3.49     .702
  Waist circumference (cm)       86.79 ± 8.86        87.46 ± 10.85      .842   86.05 ± 9.2      85.53 ± 10.8     .889
  Duration (years)               4.00 ± 3.66         3.59 ± 5.73        .801   4.67 ± 3.66      3.50 ± 6.02      .530
  FPG (mg/dL)                    143.89 ± 31.19      139.65 ± 27.36     .672   146.73 ± 33.54   137.21 ± 28.34   .418
  HbA1c (%)                      7.38 ± 0.71         7.21 ± 0.59        .441   7.37 ± 0.75      7.14 ± 0.57      .375
  OAD use (%)                    0                   0                         0                0                
  Systolic BP (mm Hg)            130.44 ± 10.99      128.24 ± 9.26      .526   131.40 ± 11.56   127.93 ± 8.91    .376
  Diastolic BP (mm Hg)           78.89 ± 6.91        78.47 ± 8.24       .871   78.67 ± 7.47     78.43 ± 9.10     .939
  Total‐cholesterol (mg/dL)      217.28 ± 38.44      224.76 ± 45.15     .600   219.13 ± 36.38   217.29 ± 44.89   .904
  HDL‐cholesterol (mg/dL)        59.17 ± 16.19       61.41 ± 15.74      .680   61.53 ± 16.08    63.21 ± 16.78    .785
  Triglyceride (mg/dL)           157.39 ± 96.03      120.65 ± 34.94     .143   148.20 ± 99.38   112.79 ± 32.47   .208
  DPP‐4 activity (nmol/mL/min)   8.73 ± 1.66         9.02 ± 1.95        .639   8.76 ± 1.72      9.19 ± 2.09      .542

Each value represents mean ± standard deviation.

Abbreviations: BMI, body mass index; BP, blood pressure; DPP‐4, dipeptidyl peptidase‐4; FPG, fasting plasma glucose; HDL, high density lipoprotein; OAD, oral anti‐diabetic drugs.

MTT were performed to increase GIP and GLP‐1 prior to SHGCT. Glucose levels were similar between the linagliptin and liraglutide groups at V2, and were decreased similarly at V3, to a greater degree in the liraglutide group (Table S1 and Figure S2). C‐peptide and ISR were significantly higher in the liraglutide group at V2 and V3, and were similarly enhanced at V3 compared to V2 in both groups. Glucagon tended to be higher in the liraglutide group at V2 and V3, but was similarly suppressed at V3 compared to V2 in both groups. Intact GIP levels were similar in the two groups at V2, and were increased at V3 only in the linagliptin group; GIP levels were similar between the two groups at V2 and V3 (Table S1 and Figure S3). Total and intact GLP‐1 were not determined in the liraglutide group throughout the study because of the difficulty in differentiating liraglutide from endogenous GLP‐1.

SHGCT were performed immediately after MTT. Glucose levels at V2 and V3 in both groups were similarly decreased during euglycaemic and hypoglycaemic phases (Figure S4). After discontinuation of insulin infusion at 255 minutes, blood glucose recovered similarly at V2 and V3 in both groups. The recovery from hypoglycaemia exhibited no significant difference between groups and glucose infusion rates (IIR) from 255 to 300 minutes were similar between groups and between visits. Glucose infusion rates were also similar between groups and between visits (Figure S7). ISR at V3 was higher than that at V2 during the hyperglycaemic and euglycaemic phases, but there was no difference in ISR during the hypoglycaemic phase between the two groups or between visits (Table [2](#dom12817-tbl-0002){ref-type="table-wrap"} and Figure S4). During the hyperglycaemic and euglycaemic phases, glucagon at V2 and V3 were nearly unchanged and were similar in both groups (Table [2](#dom12817-tbl-0002){ref-type="table-wrap"} and Figure S5). Glucagon increased rapidly during the hypoglycaemic phase and there was no difference in glucagon response between groups or between visits. Total GIP levels were similar between groups at V2 and V3. Intact GIP levels were similar between groups at V2, and were increased only in the linagliptin group at V3. GH, cortisol, epinephrine and norepinephrine were increased during the latter half of the hypoglycaemic phase at V2 and V3 (Table [2](#dom12817-tbl-0002){ref-type="table-wrap"} and Figure S6). The changes in GH, cortisol, epinephrine and norepinephrine at V3 were less than those at V2 in both groups. The overall results in the FAS population were fully consistent with those of the PPS population (data not shown).

###### 

Response to hypoglycaemia in the per protocol population

                                                                      Linagliptin   Liraglutide   *Δ*(V3 ‐ V2)                                                                                                                  
  ------------------------------------ ------------------------------ ------------- ------------- -------------- --------- --------- ---------- ---------- --------- ------- ----------- --------- ---------- --------- ------- ------
  ISR                                  *Δ*{225 ‐ 255} (pmol / m^2^)   − 84.85       24.21         − 105.90       17.37     .493      − 105.70   23.42      − 95.82   19.84   .733        − 21.05   29.89      9.89      28.36   .461
  AUC{225 ‐ 255} (pmol / m^2^ × min)   2057.94                        317.03        2010.04       250.84         .907      1824.22   283.26     2135.27    286.97    .463    − 47.90     403.86    311.05     411.03    .539    
  Glucagon                             *Δ*{225 ‐ 255} (pg / mL)       70.87         16.59         55.73          10.75     .393      56.43      12.24      62.21     13.25   .284        − 15.13   17.16      5.79      5.18    .260
  AUC{225 ‐ 300} (pg / mL × min)       9151.00                        930.08        8653.50       700.72         .358      9051.43   787.85     8776.61    786.45    .226    − 497.50    523.15    − 274.82   216.39    .699    
  Growth hormone                       *Δ*{225 ‐ 255} (ng / mL)       5.07          1.04          2.48           0.87      .023      2.58       0.80       0.94      0.39    .081        − 2.60    1.01       − 1.65    0.87    .486
  AUC{225 ‐ 300} (ng / mL × min)       329.10                         45.03         256.65        48.81          .222      275.08    49.58      219.30     47.28     .264    − 72.44     56.62     − 55.78    47.72     .825    
  Cortisol                             *Δ*{225 ‐ 255} (µg / dL)       7.09          1.49          3.05           1.12      .035      3.34       1.47       1.51      0.96    .315        − 4.05    1.74       − 1.83    1.75    .377
  AUC{225 ‐ 300} (µg / dL × min)       1302.25                        71.33         970.80        65.19          .000      1225.45   103.09     907.61     64.00     .001    − 331.45    68.13     − 317.84   77.99     .896    
  Epinephrine                          *Δ*{225 ‐ 255} (ng / mL)       0.98          0.22          0.53           0.14      .103      0.72       0.20       0.33      0.09    .091        − 0.45    0.16       − 0.39    0.12    .769
  AUC{225 ‐ 300} (ng / mL × min)       36.25                          7.56          20.25         3.60           .006      28.23     6.19       13.23      2.25      .004    − 16.00     4.92      − 15.00    4.35      .881    
  Norepinephrine                       *Δ*{225 ‐ 255} (ng / mL)       0.29          0.07          0.14           0.04      .041      0.23       0.05       0.15      0.04    .079        − 0.15    0.06       − 0.08    0.04    .422
  AUC{225 ‐ 300} (ng / mL × min)       30.09                          3.37          27.90         2.02           .277      29.76     2.19       27.96      1.78      .313    − 2.19      1.93      − 1.80     1.72      .883    
  Total GIP                            *Δ*{225 ‐ 255} (pmol / L)      67.07         35.14         60.08          23.76     .871      − 66.22    58.52      − 29.28   29.28   .579        − 6.98    34.20      36.94     48.61   .452
  AUC{225 ‐ 300} (pmol / L × min)      14196.60                       2810.26       13006.23      1441.86        .620      9828.73   766.24     14330.31   1533.50   .014    − 1190.37   2349.66   4501.58    1581.68   .058    
  Intact GIP                           *Δ*{225 ‐ 255} (pmol / L)      9.17          5.50          11.71          6.34      .765      − 8.04     8.08       0.13      5.57    .413        2.54      7.37       8.17      7.06    .587
  AUC{225 ‐ 300} (pmol / L × min)      1434.30                        296.39        3386.85       436.02         \<.0001   1096.42   150.22     1528.59    173.40    .065    1952.55     335.06    432.17     214.47    .001    
  Total GLP‐1                          *Δ*{225 ‐ 255} (pmol / L)      2.19          0.71          2.50           1.00      .804      ND         ND                   0.31    0.92        ND                                     
  AUC{225 ‐ 300} (pmol / L × min)      433.04                         45.82         430.15        41.01          .923                                      − 2.89    29.34   ND                                                 
  Intact GLP‐1                         *Δ*{225 ‐ 255} (pmol / L)      − 0.71        0.26          0.61           0.69      .091      ND         ND                   1.32    0.70        ND                                     
  AUC{225 ‐ 300} (pmol / L × min)      95.23                          10.54         225.71        20.42          \<.0001   ND        ND                    130.48    18.94   ND                                                 

Abbreviations: AUC, area under the curve; CPR, C‐peptide reactivity; GIP, glucose‐dependent insulinotropic polypeptide; GLP‐1, glucagon‐like peptide‐1; ISR, insulin secretion rate; S.E., standard error; V2, visit 2; V3, visit3.

3.1. Safety {#dom12817-sec-0008}
-----------

AE and SAE were analysed in the FAS population. No AE was reported in the linagliptin group. One subject in the liraglutide group experienced nausea, which was assessed as non‐serious and treatment‐related. No SAE was experienced by any individual in either group.

4. DISCUSSION {#dom12817-sec-0009}
=============

A main finding of this study comparing linagliptin with liraglutide in Japanese individuals with T2D confirms our general understanding that incretin therapies do not prevent hypoglycaemia‐induced glucagon secretion, as was previously reported for the DPP‐4 inhibitor vildagliptin and the GLP‐1R agonists albiglutide and lixisenatide in individuals with T2D.[11](#dom12817-bib-0011){ref-type="ref"}, [12](#dom12817-bib-0012){ref-type="ref"}, [13](#dom12817-bib-0013){ref-type="ref"}, [14](#dom12817-bib-0014){ref-type="ref"} This supports the notion that these therapies are not associated with increased risk of hypoglycaemia. Importantly, the present study shows that linagliptin did not enhance hypoglycaemia‐induced glucagon secretion even though biologically intact GIP was significantly elevated. It has been shown previously that vildagliptin enhanced hypoglycaemia‐induced glucagon secretion in drug‐naive individuals with T2.[11](#dom12817-bib-0011){ref-type="ref"} Discrepancies between that study and ours could be explained by the following possibilities. First, different DPP‐4 inhibitors were used for different treatment periods (ie, vildagliptin, 4 weeks; linagliptin, 2 weeks). Second, different comparisons were made (ie, vildagliptin vs placebo; linagliptin vs liraglutide; before vs after linagliptin treatment). Third, different ethnic groups were studied (ie, Caucasian vs Japanese); T2D in East Asians, including Japanese, is characterized primarily by β‐cell dysfunction with less adiposity and it differs phenotypically from T2D in Caucasians,[15](#dom12817-bib-0015){ref-type="ref"} showing greater HbA1c reduction in response to DPP‐4 inhibitors and GLP‐1R agonists.[16](#dom12817-bib-0016){ref-type="ref"}, [17](#dom12817-bib-0017){ref-type="ref"} Finally, subjects with different baseline HbA1c levels were enrolled (ie, mean HbA1c 6.3% vs 7.3%). It could therefore be possible that glucagonotropic effects of GIP might be impaired by chronic hyperglycaemia, similarly to the insulinotropic effects of GIP.[18](#dom12817-bib-0018){ref-type="ref"} Interestingly, enhancement of the hypoglycaemia‐induced glucagon response by GIP or vildagliptin was observed in T2D individuals with mean baseline HbA1c values between 6.3% and 6.5%,[7](#dom12817-bib-0007){ref-type="ref"}, [11](#dom12817-bib-0011){ref-type="ref"} but there was little enhancement by vildagliptin in individuals with T2D with a mean baseline HbA1c value of 7.7%.[14](#dom12817-bib-0014){ref-type="ref"} Further investigations are required to clarify the discrepancies between these two studies.

In the current study, the hypoglycaemia‐induced responses of the counter‐regulatory hormones GH, cortisol, epinephrine and norepinephrine were attenuated at V3 compared to those at V2, which is similar to the effect of DPP‐4 inhibitor linagliptin and the GLP‐1 receptor agonist liraglutide (Table [2](#dom12817-tbl-0002){ref-type="table-wrap"} and Figure S6). The lack of placebo or euglycaemic control groups in our study does not permit exclusion of the possibility that the subjects' experiences at V2 might affect the counter‐responses of GH, cortisol, epinephrine and norepinephrine seen at V3. Furthermore, the variable IIR could result in different insulin levels between tests that might affect responses of the counter‐regulatory hormones. However, a recent study in T2D individuals reported suppressive effects on hypoglycaemia‐induced sympatho‐adrenal response after treatment with the GLP‐1 receptor agonist lixisenatide,[13](#dom12817-bib-0013){ref-type="ref"} which are similar to our present findings. Co‐administration of some incretin therapies in insulin and/or sulfonylurea‐treated individuals with T2D would seem to have potential for preventing hypoglycaemia‐induced release of cortisol and catecholamine, and thus possibly reduce cardiovascular event risks. However, further investigations are needed to clarify the underlying mechanisms and clinical relevance of the current findings, as most previous studies on incretin therapies did not show similar suppressive effects in individuals with T2D or type 1 diabetes.[11](#dom12817-bib-0011){ref-type="ref"}, [19](#dom12817-bib-0019){ref-type="ref"}, [20](#dom12817-bib-0020){ref-type="ref"} In conclusion, neither the DPP‐4 inhibitor linagliptin nor the GLP‐1 receptor agonist liraglutide impaired the alpha‐cell responsiveness to hypoglycaemia in Japanese individuals with T2D.
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**Figure S1**. CONSORT Flow diagram of the study.

###### 

Click here for additional data file.

###### 

**Figure S2**. Glucose, C‐peptide, insulin secretion rate (ISR) and glucagon during meal tolerance tests in the per protocol population.
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**Figure S3**. Glucose‐dependent insulinotropic polypeptide (GIP) and glucagon‐like peptide‐1 (GLP‐1) during meal tolerance tests in the per protocol population.
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**Figure S4**. Glucose, C‐peptide, insulin secretion rate (ISR) and insulin infusion rate (IIR) during three‐step hyperinsulinemic clamp tests in the per protocol population.
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**Figure S5**. Glucagon, glucose‐dependent insulinotropic polypeptide (GIP) and glucagon‐like peptide‐1 (GLP‐1) during three‐step hyperinsulinemic clamp tests in the per protocol population.
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**Figure S6**. Growth hormone, cortisol, norepinephrine and epinephrine during hyperinsulinemic clamp tests (from 225 to 300 minutes) in the per protocol population.
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**Figure S7**. Glucose infusion rate (GIR) and GIR area‐under‐the curve (GIR‐AUC) after discontinuation of insulin infusion in the per protocol population.
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**Table S1**. Response to meals in the per protocol population.
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**File S1**. Blood sampling and measurement of hormones.
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